drugset / Trial / NCT00912054

DuoTrav APS Versus XALACOM® in Ocular Surface Health

NCT00912054

Phase 3 Terminated 240 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate superiority of DuoTrav APS over XALACOM® in Ocular Surface Health in patients with open angle glaucoma or ocular hypertension.

Timeline

Start
2010-03
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule 50 ug/ml Other
Subject Travoprost Other / unclassified 40 ug/ml Other
Background Timolol Other / unclassified 5 mg/ml Other